NAMSA expands US footprint with Labcorp medical device testing acquisition
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Subscribe To Our Newsletter & Stay Updated